Tesamorelin
Growth Hormone
Also known as: Egrifta, TH9507
Tesamorelin is a synthetic analog of human growth hormone–releasing hormone (GHRH) and is FDA-approved for the reduction of excess visceral adipose tissue in adults with HIV-associated lipodystrophy. Beyond its approved indication, it has been investigated in metabolic, hepatic, and cognitive research contexts. Educational reference only; not medical advice.
- Dose in studies
- 1-2 mg per day
- Frequency
- Daily
- Cycle length
- Continuous under medical supervision
- Half-life
- 26-38 minutes
- Research level
- 4/5 – Well researched
Frequently asked questions about Tesamorelin
What is Tesamorelin?
Tesamorelin is a synthetic analog of human growth hormone–releasing hormone (GHRH) and is FDA-approved for the reduction of excess visceral adipose tissue in adults with HIV-associated lipodystrophy. Beyond its approved indication, it has been investigated in metabolic, hepatic, and cognitive research contexts. Educational reference only; not medical advice.
What is the half-life of Tesamorelin?
The half-life of Tesamorelin is 26-38 minutes.
What dosage of Tesamorelin has been studied?
Described in research: 1-2 mg per day, frequency: Daily. This is not a medical recommendation.
How long is a Tesamorelin cycle?
Typical cycle length in studies: Continuous under medical supervision.
What are the side effects of Tesamorelin?
Injection site reactions: Redness, itching, and induration at injection site. The most commonly reported side effect in clinical trials (~25%). Rotate sites and use proper technique. · Joint pain/arthralgia: Reported by ~10% of clinical trial participants. Related to GH activity. Usually mild and dose-dependent. · Peripheral edema: Swelling in hands and feet from fluid retention. More common in…
How well researched is Tesamorelin?
Well researched (4/5). Large phase 3 trials or regulatory approval; long-term data still limited.